{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:29:10Z","timestamp":1778603350880,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.rcsop.2022.100130","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T18:21:58Z","timestamp":1647800518000},"page":"100130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A descriptive analysis of concomitant opioid and benzodiazepine medication use and associated adverse drug events in United States adults between 2009 and 2018"],"prefix":"10.1016","volume":"5","author":[{"given":"Kathryn K.","family":"Marwitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa","family":"Noureldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcsop.2022.100130_bb0005","author":"Benzodiazepines and Opioids. National Institute on Drug Abuse"},{"key":"10.1016\/j.rcsop.2022.100130_bb0010","article-title":"Association between benzodiazepine use with or without Opioid use and all-cause mortality in the United States, 1999-2015","volume":"2020","author":"Xu","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rcsop.2022.100130_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic pain \u2014 United States","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Morb Mortal Recomm Rep"},{"key":"10.1016\/j.rcsop.2022.100130_bb0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/DHPS.S214771","article-title":"Opioids and frequency counts in the US Food and Drug Administration adverse event reporting system (FAERS) database: a quantitative view of the epidemic","volume":"11","author":"Veroni","year":"2019","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.rcsop.2022.100130_bb0025","article-title":"Predictors of serious adverse drug events from opioids: results from the Food and Drug Administration adverse events reporting system","author":"McDonald","year":"2021","journal-title":"J Am Assoc Nurse Pract"},{"key":"10.1016\/j.rcsop.2022.100130_bb0030","author":"[dataset] FDA Adverse Event Reporting System (FAERS)"},{"key":"10.1016\/j.rcsop.2022.100130_bb0035","author":"[dataset] Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.rcsop.2022.100130_bb0040","author":"National Health and Nutrition Examination Survey"},{"key":"10.1016\/j.rcsop.2022.100130_bb0045","author":"National Health and Nutrition Examination Survey: Analytic Guidelines, 2011\u20132014 and 2015\u20132016"},{"key":"10.1016\/j.rcsop.2022.100130_bb0050","author":"National Health and Nutrition Examination Survey: Analytic Guidelines, 2011-2016"},{"key":"10.1016\/j.rcsop.2022.100130_bb0055","author":"National health and nutrition examination survey. Analytic guidelines, 1999\u2013-2010"},{"key":"10.1016\/j.rcsop.2022.100130_bb0060","series-title":"National Center for Health Statistics Data Presentation Standards for Proportions. National Center for Health Statistics. Vital Health Stat","volume":"2","author":"Parker","year":"2017"},{"key":"10.1016\/j.rcsop.2022.100130_bb0065","series-title":"Code of Federal Regulations. Title 21","article-title":"\u00a7 314.80 Postmarketing reporting of adverse drug experiences","year":"2021"},{"key":"10.1016\/j.rcsop.2022.100130_bb0070","doi-asserted-by":"crossref","DOI":"10.1007\/s11916-016-0564-x","article-title":"Current state of Opioid therapy and abuse","volume":"20","author":"Manchikanti","year":"2016","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.rcsop.2022.100130_bb0075","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and Opioid-involved overdose deaths - United States, 2010-2015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.rcsop.2022.100130_bb0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1176\/appi.ajp.2015.15020262","article-title":"Prescription opioid misuse, abuse, and treatment in the United States: An Update","volume":"173","author":"Brady","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rcsop.2022.100130_bb0085","series-title":"New Safety Measures Announced for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepines","year":"2016"},{"key":"10.1016\/j.rcsop.2022.100130_bb0090","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamapsychiatry.2019.2563","article-title":"Opioid and benzodiazepine Coprescribing in the United States before and after US Food and Drug Administration boxed warning","volume":"76","author":"Zhang","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.rcsop.2022.100130_bb0095","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.amepre.2015.02.020","article-title":"Trends in Opioid Analgesic-Prescribing Rates by Specialty, U.S., 2007-2012","volume":"49","author":"Levy","year":"2015","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.rcsop.2022.100130_bb0100","series-title":"AMA partners with the administration to halt nation's opioid crisis","year":"2015"},{"key":"10.1016\/j.rcsop.2022.100130_bb0105","article-title":"Prescribing limits across the states","author":"Bulloch","year":"2019","journal-title":"Pharmacy Times"},{"key":"10.1016\/j.rcsop.2022.100130_bb0110","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.japh.2016.12.075","article-title":"A nationwide pharmacy chain responds to the opioid epidemic","volume":"57","author":"Shafer","year":"2017","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.rcsop.2022.100130_bb0115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amepre.2016.02.014","article-title":"Trends in the concomitant Prescribing of opioids and benzodiazepines, 2002-2014","volume":"51","author":"Hwang","year":"2016","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.rcsop.2022.100130_bb0120","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.pmrj.2018.09.026","article-title":"Concomitant use of opioids and benzodiazepines in the outpatient setting","volume":"11","author":"Simon","year":"2019","journal-title":"PM R"},{"key":"10.1016\/j.rcsop.2022.100130_bb0125","doi-asserted-by":"crossref","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","article-title":"Vital signs: changes in Opioid Prescribing in the United States, 2006\u20132015","volume":"66","author":"Guy","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.rcsop.2022.100130_bb0130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamainternmed.2018.6721","article-title":"Assessment of racial\/ethnic and income disparities in the prescription of opioids and other controlled medications in California","volume":"179","author":"Friedman","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.rcsop.2022.100130_bb0135","doi-asserted-by":"crossref","first-page":"e187399","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in outpatient benzodiazepine prescribing in the United States","volume":"2","author":"Agarwal","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rcsop.2022.100130_bb0140","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1073\/pnas.1722023115","article-title":"Declining mental health among disadvantaged Americans","volume":"115","author":"Goldman","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.rcsop.2022.100130_bb0145","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(17)30398-7","article-title":"Inequality and the health-care system in the USA","volume":"389","author":"Dickman","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.rcsop.2022.100130_bb0150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The weber effect and the United States Food and Drug Administration\u2019s adverse event reporting system (FAERS): analysis of sixty-two drugs approved","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.rcsop.2022.100130_bb0155","series-title":"New Drugs at FDA: CDER\u2019s New Molecular Entities and New Therapeutic Biological Products","year":"2021"},{"key":"10.1016\/j.rcsop.2022.100130_bb0160","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","article-title":"Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS)","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.rcsop.2022.100130_bb0165","first-page":"135","article-title":"US food and drug administration safety advisories and reporting to the adverse event reporting system (FAERS)","volume":"34","author":"Moore","year":"2020","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.rcsop.2022.100130_bb0170","series-title":"2018 Annual Report of the American Association of Poison Control Centers\u2019 National Poison Data System (NPDS): 36th Annual Report 57","first-page":"1220","author":"Gummin","year":"2019"},{"key":"10.1016\/j.rcsop.2022.100130_bb0175","series-title":"Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 32nd Annual Report 54","first-page":"962","author":"Mowry","year":"2014-2016"},{"key":"10.1016\/j.rcsop.2022.100130_bb0180","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1056\/NEJMp1710756","article-title":"Drug Companies\u2019 liability for the Opioid epidemic","volume":"24","author":"Haffajee","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rcsop.2022.100130_bb0185","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s40264-019-00834-1","article-title":"The impact of litigation-associated reports on signal identification in the US FDA\u2019s adverse event reporting system","volume":"42","author":"Mu\u00f1oz","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.rcsop.2022.100130_bb0190","author":"NHANES"},{"key":"10.1016\/j.rcsop.2022.100130_bb0195","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","article-title":"Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-a nation-wide register-based open cohort study","author":"Abrahamsson","year":"2017","journal-title":"Drug Alcohol Depend"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276622000294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276622000294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T08:30:37Z","timestamp":1757406637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276622000294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":39,"alternative-id":["S2667276622000294"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2022.100130","relation":{},"ISSN":["2667-2766"],"issn-type":[{"value":"2667-2766","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A descriptive analysis of concomitant opioid and benzodiazepine medication use and associated adverse drug events in United States adults between 2009 and 2018","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2022.100130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100130"}}